Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
5 Jun, 20:00
NYSE NYSE
$
232. 77
+4.6
+2.016%
$
564.11B Market Cap
29.06 P/E Ratio
0.69% Div Yield
5.64M Volume
9.91 Eps
$ 228.17
Previous Close
Add Transaction
Day Range
229 235.21
Year Range
149.04 251.71
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Johnson & Johnson Q2 Earnings Preview: Scrutinizing Its Earnings Quality

Johnson & Johnson Q2 Earnings Preview: Scrutinizing Its Earnings Quality

Johnson & Johnson will announce its Q2 2024 results on Wednesday, July 17 before the market opens. In this update, I share what to expect from JNJ's Q2 results and put previous results into perspective. In the main part of the article, I will take a close look at JNJ's earnings adjustments, amid the significant deviation from GAAP earnings (+46% median since 2014).

Seekingalpha | 1 year ago
3 Undervalued Stocks Set to Outperform the Market in 2024

3 Undervalued Stocks Set to Outperform the Market in 2024

During stock investing, having a list of the top undervalued stocks can offer lucrative opportunities for value growth and portfolio stability. Here are three stocks whose intrinsic value exceeds their current market price, promising potential gains as the market corrects itself.

Investorplace | 1 year ago
AI picks 3 must-have dividend stocks for 2024 H2

AI picks 3 must-have dividend stocks for 2024 H2

In an era where some investors prioritize stable income and reliable returns, artificial intelligence (AI) has identified three standout dividend stocks poised to shine in the latter half of 2024.

Finbold | 1 year ago
7 Diversified Income Powerhouses for Lifelong Cash Flow

7 Diversified Income Powerhouses for Lifelong Cash Flow

Diversified income stocks are a smart choice for investors seeking lifelong cash flow. They offer a reliable stream of income from multiple sources and provide stability and growth potential in any market condition.

Investorplace | 1 year ago
Johnson & Johnson: Remaining A Buy Despite Remaining Risks

Johnson & Johnson: Remaining A Buy Despite Remaining Risks

Johnson & Johnson reported solid first quarter results and is also expecting mid-single digit growth for the full year. The company is facing risks right now, especially from the litigations due to the talc products, and breaking the support line is also a rather bearish sign. But the stock seems slightly undervalued at this point, and Johnson & Johnson is probably a good investment for investors seeking stability and a bond-like investment.

Seekingalpha | 1 year ago
J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?

J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?

A new investor should avoid buying J&J (JNJ) stock right now due to its legal troubles. However, those who already own the stock may stay invested as the company is generating decent sales growth.

Zacks | 1 year ago
Johnson & Johnson: Put Selling Can Yield A Potential 9.8% Return

Johnson & Johnson: Put Selling Can Yield A Potential 9.8% Return

Johnson & Johnson's underlying business has a stable long-term outlook and the stock has a low volatility profile, which makes it an ideal platform for selling put options. The company is trading at a highly attractive valuation, which provides a solid margin of error. Selling put options does sacrifice capital appreciation, but with a nearly 10% annualized yield on offer, this opportunity appears to be a win-win to us.

Seekingalpha | 1 year ago
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off

2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off

Dividends can boost your portfolio returns. Johnson & Johnson is a classic example of a value stock with a faithful dividend history.

Fool | 1 year ago
Cancer victims lose bid to block proposed J&J talc bankruptcy

Cancer victims lose bid to block proposed J&J talc bankruptcy

A federal judge on Friday rejected a bid by a group of cancer victims to block Johnson & Johnson from pursuing a proposed bankruptcy settlement of tens of thousands of lawsuits alleging the company's baby powder and other talc products contain cancer-causing asbestos.

Reuters | 1 year ago
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 year ago
Is Johnson & Johnson Stock a Buy?

Is Johnson & Johnson Stock a Buy?

Johnson & Johnson is trying a new approach to resolve thousands of outstanding talc lawsuits. The company's operations are growing in the mid-single digits, and investors can expect more of the same in the years ahead.

Fool | 1 year ago
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors

Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors

Johnson & Johnson (JNJ) closed the most recent trading day at $147.19, moving -1.29% from the previous trading session.

Zacks | 1 year ago
Loading...
Load More